Richard Hirsh Email Address

Industrial Hygienist

Nektar Therapeutics is a biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. The Companys product pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. Nektars research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. It creates its drug candidates by using its chemistry platform to modify the chemical structure of drugs using polymer conjugates. Nektars drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

Certified in the comprehensive practice of industrial hygiene. Director for EH&S at Nektar Therapeutics. Responsible for global EHS program development, standards, training, technical assistance, API exposure assessments, and other EHS activities. Previously at Stiefel Laboratories as Global H&S Manager for 9 worldwide locations. Rich previously worked at Rohm and Haas Company in the Global EHS and Sustainable Development department. Responsible for IH technical assistance to over 130 locations worldwide, training, developing corporate EHS policies and standards, conducting EHS compliance audits. AIHA Fellow. Past- President of the Northern California Section of the American Industrial Hygiene Association. Chair of the Developing World Outreach Initiative. Chair of the AIHA International Affairs Committee. Chair of the AIHA Asia-Pacific Conference 2013 Planning Committee.